Rissiek Anne, Schulze Christian, Bacher Ulrike, Schieferdecker Aneta, Thiele Benjamin, Jacholkowski Anita, Flammiger Anna, Horn Christiane, Haag Friedrich, Tiegs Gisa, Zirlik Katja, Trepel Martin, Tolosa Eva, Binder Mascha
Institute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Int J Cancer. 2014 Nov 15;135(10):2370-9. doi: 10.1002/ijc.28884. Epub 2014 Apr 18.
Antitumor immunity in chronic lymphocytic leukemia (CLL) is hampered by highly dysfunctional T-cells. Although certain T-cell subsets have been reported to be of prognostic significance in this disease, their interplay is complex and it remains incompletely understood which of these subsets significantly drive CLL progression. Here, we determined immunological profiles of 24 circulating T-cell subsets from 79 untreated individuals by multiparametric flow cytometry. This screening cohort included healthy donors, patients with monoclonal B-cell lymphocytosis (MBL), Rai 0 CLL and advanced CLL. We applied multidimensional scaling analysis as rigorous and unbiased statistical tool to globally assess the composition of the circulating T-cell environment and to generate T-cell scores reflecting its integrity. These scores allowed clear distinction between advanced CLL and healthy controls, whereas both MBL and Rai 0 CLL showed intermediate scores mirroring the biological continuum of CLL and its precursor stages. T-cell stimulation and suppression assays as well as longitudinal T-cell profiling showed an increasingly suppressive regulatory function initiating at the MBL stage. Effector function was impaired only after transition to CLL and partially recovered after chemoimmunotherapy. In an independent validation cohort of 52 untreated CLL cases, aberrant T-cell profiles were significantly associated with shorter time to treatment independently of other prognostic parameters. Random forest modeling predicted regulatory T-cell, gamma/delta and NKT-cells, as well as exhaustion of the CD8+ subset as potential drivers of progression. Our data illustrate a pathological T-cell environment in MBL that evolves toward a more and more suppressive and prognostically relevant profile across the disease stages.
慢性淋巴细胞白血病(CLL)中的抗肿瘤免疫受到高度功能失调的T细胞的阻碍。尽管据报道某些T细胞亚群在这种疾病中具有预后意义,但其相互作用很复杂,目前仍不完全清楚这些亚群中哪些会显著推动CLL进展。在这里,我们通过多参数流式细胞术确定了79名未经治疗个体的24种循环T细胞亚群的免疫谱。该筛查队列包括健康供体、单克隆B细胞淋巴细胞增多症(MBL)患者、Rai 0期CLL患者和晚期CLL患者。我们应用多维标度分析作为严谨且无偏倚的统计工具,以全面评估循环T细胞环境的组成,并生成反映其完整性的T细胞评分。这些评分能够清晰地区分晚期CLL和健康对照,而MBL和Rai 0期CLL均显示出中间评分,反映了CLL及其前驱阶段的生物学连续性。T细胞刺激和抑制试验以及纵向T细胞分析表明,从MBL阶段开始,调节功能的抑制作用越来越强。效应功能仅在转变为CLL后受损,并在化疗免疫治疗后部分恢复。在一个由未治疗的52例CLL病例组成的独立验证队列中,异常的T细胞谱与较短的治疗时间显著相关,且独立于其他预后参数。随机森林建模预测调节性T细胞、γ/δT细胞和自然杀伤T细胞以及CD8 +亚群的耗竭是进展的潜在驱动因素。我们的数据表明,MBL中存在病理性T细胞环境,该环境在疾病各阶段逐渐演变为越来越具有抑制性且与预后相关的特征。